Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

258 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Implementing personalized medicine in a cancer center.
Fenstermacher DA, Wenham RM, Rollison DE, Dalton WS. Fenstermacher DA, et al. Among authors: dalton ws. Cancer J. 2011 Nov-Dec;17(6):528-36. doi: 10.1097/PPO.0b013e318238216e. Cancer J. 2011. PMID: 22157297 Free PMC article. Review.
Proteomic contributions to personalized cancer care.
Koomen JM, Haura EB, Bepler G, Sutphen R, Remily-Wood ER, Benson K, Hussein M, Hazlehurst LA, Yeatman TJ, Hildreth LT, Sellers TA, Jacobsen PB, Fenstermacher DA, Dalton WS. Koomen JM, et al. Among authors: dalton ws. Mol Cell Proteomics. 2008 Oct;7(10):1780-94. doi: 10.1074/mcp.R800002-MCP200. Epub 2008 Jul 29. Mol Cell Proteomics. 2008. PMID: 18664563 Free PMC article. Review.
Subsequent primary malignancies and acute myelogenous leukemia transformation among myelodysplastic syndrome patients treated with or without lenalidomide.
Rollison DE, Shain KH, Lee JH, Hampras SS, Fulp W, Fisher K, Al Ali NH, Padron E, Lancet J, Xu Q, Olesnyckyj M, Kenvin L, Knight R, Dalton W, List A, Komrokji RS. Rollison DE, et al. Cancer Med. 2016 Jul;5(7):1694-701. doi: 10.1002/cam4.721. Epub 2016 Apr 20. Cancer Med. 2016. PMID: 27098006 Free PMC article.
A parallel-arm phase I trial of the humanised anti-IGF-1R antibody dalotuzumab in combination with the AKT inhibitor MK-2206, the mTOR inhibitor ridaforolimus, or the NOTCH inhibitor MK-0752, in patients with advanced solid tumours.
Brana I, Berger R, Golan T, Haluska P, Edenfield J, Fiorica J, Stephenson J, Martin LP, Westin S, Hanjani P, Jones MB, Almhanna K, Wenham RM, Sullivan DM, Dalton WS, Gunchenko A, Cheng JD, Siu LL, Gray JE. Brana I, et al. Among authors: dalton ws. Br J Cancer. 2014 Nov 11;111(10):1932-44. doi: 10.1038/bjc.2014.497. Epub 2014 Oct 7. Br J Cancer. 2014. PMID: 25290091 Free PMC article. Clinical Trial.
Use of the Total Cancer Care System to Enrich Screening for CD30-Positive Solid Tumors for Patient Enrollment Into a Brentuximab Vedotin Clinical Trial: A Pilot Study to Evaluate Feasibility.
Li B, Eschrich SA, Berglund A, Mitchell M, Fenstermacher D, Danaee H, Dai H, Sullivan D, Trepicchio WL, Dalton WS. Li B, et al. Among authors: dalton ws. JMIR Res Protoc. 2017 Mar 20;6(3):e45. doi: 10.2196/resprot.7289. JMIR Res Protoc. 2017. PMID: 28320689 Free PMC article.
On the eve of personalized medicine in oncology.
Yeatman TJ, Mule J, Dalton WS, Sullivan D. Yeatman TJ, et al. Among authors: dalton ws. Cancer Res. 2008 Sep 15;68(18):7250-2. doi: 10.1158/0008-5472.CAN-08-1374. Cancer Res. 2008. PMID: 18794109 Free PMC article. No abstract available.
258 results